Cangene to host year-end fiscal 2008 conference call, Friday October 17, 2008 at 11:00 a.m. E.D.T.

    Listed TSX, Symbol: CNJ

    TORONTO and WINNIPEG, Oct. 15 /CNW/ - Cangene Corporation today announces
that it intends to host a conference call on Friday, October 17, 2008 at
11:00 a.m. E.D.T. to discuss its financial results for the fiscal year, ended
July 31, 2008. The Company intends to disclose its financial results via news
release after market close on Thursday, October 16, 2008.
    To access the conference call by telephone, dial 416-644-3414 or
1-800-732-9303. Please connect approximately 15 minutes prior to the beginning
of the call to ensure participation. The conference call will be archived for
replay until Friday, October 24, 2008, at midnight. To access the archived
conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation
number 21286309 followed by the number sign.
    A live audio webcast of the conference call will be available at and Please connect at least 15 minutes prior
to the conference call to ensure adequate time for any software download that
may be required to join the webcast. The webcast will be archived at the above
web sites for 90 days.

    About Cangene Corporation

    Cangene is one of Canada's largest and earliest biopharmaceutical
companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
Cangene has approximately 700 employees in eight locations across North
America and its products are sold worldwide. It operates three large
manufacturing facilities - two in Winnipeg, Manitoba and one in Baltimore,
Maryland - where it produces its own products and undertakes contract
manufacturing for a number of companies. Cangene operates three U.S. and one
Canadian plasma-collection facilities. In addition, it has a regulatory
affairs, sales and investor relations office in Toronto, Ontario.
    Cangene is focused on developing therapeutics for infectious diseases,
and the Company uses patented manufacturing processes to produce
plasma-derived and recombinant therapeutic proteins. Cangene has five FDA
and/or Health Canada-approved products. In addition, the Company has several
more products in development at various stages. Three of Cangene's products
have been accepted into the U.S. Strategic National Stockpile-botulism
antitoxin, anthrax immune globulin and vaccinia immune globulin, a product
used to counteract certain complications that may arise from smallpox
    Capitalizing on its drug manufacturing expertise, Cangene also operates a
significant contract research and manufacturing business using its Winnipeg
facilities and the resources of Baltimore, Maryland-based Chesapeake
Biological Laboratories, Inc. (a wholly owned subsidiary). Cangene's website,, includes product and investor information, including past
news releases. Chesapeake's website is

    Cautionary Note Regarding Forward-looking Information

    This news release may contain forward-looking statements that are
predictive in nature and subject to risks and uncertainties that cannot be
predicted or quantified; consequently, actual results may differ materially
from past results and those expressed or implied by any forward-looking
statements. Forward-looking statements may include words such as "expects",
"plans", "will", "believes", "estimates", "intends", "may", "bodes" and other
words of similar meaning (including negative and grammatical variations) and
may relate to future financial performance, business strategies, or safety and
efficacy of unapproved products.
    Factors that could cause or contribute to such risks or uncertainties
include, but are not limited to: the regulatory environment including the
difficulty of predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of customers
including government organizations; the demand for new products and the impact
of competitive products, service and pricing; availability and cost of raw
materials, especially the cost, availability and antibody concentration in
plasma; fluctuations in operating results; government policies or actions;
progress and cost of clinical trials; reliance on key strategic relationships;
costs and possible development delays resulting from use of legal, regulatory
or legislative strategies by the Company's competitors; uncertainty related to
intellectual property protection and potential costs associated with its
defence; the Company's exposure to lawsuits, and other matters beyond control
of management. Risks and uncertainties are discussed more extensively in the
MD&A section of the Company's most recent annual report and annual information
form, which are available on the Company's website or on SEDAR at
    The cautionary statements referred to above should be considered in
connection with all written or oral statements, especially forward-looking
statements, that are made by the Company or by persons acting on its behalf
and in conjunction with its periodic filings with Securities Commissions,
including those contained in the Company's news releases and most recently
filed annual information form. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual
results could vary materially from those anticipated. The Company undertakes
no obligation to publicly make or update any forward-looking statements,
except as required by applicable law.

For further information:

For further information: please contact Ms. Jean Compton, Manager,
Investor Relations, Cangene Corporation, at (416) 675-8280 or by e-mail at

Organization Profile

Cangene Corporation

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890